# Refralon Versus Amiodarone for Cardioversion of Paroxysmal Fibrillation and Atrial Flutter

> **NCT05445297** · PHASE4 · COMPLETED · sponsor: **National Medical Research Center for Cardiology, Ministry of Health of Russian Federation** · enrollment: 60 (actual)

## Conditions studied

- Atrial Fibrillation Paroxysmal

## Interventions

- **DRUG:** Pharmacological cardioversion with Amiodarone
- **DRUG:** Pharmacological cardioversion with Refralon

## Key facts

- **NCT ID:** NCT05445297
- **Lead sponsor:** National Medical Research Center for Cardiology, Ministry of Health of Russian Federation
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-01-26
- **Primary completion:** 2023-06-30
- **Final completion:** 2023-06-30
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2025-03-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05445297

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05445297, "Refralon Versus Amiodarone for Cardioversion of Paroxysmal Fibrillation and Atrial Flutter". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05445297. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*